Lyra Therapeutics (LYRA) Projected to Post Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) will likely be announcing its Q1 2026 resultson Tuesday, August 11th. Analysts expect the company to post earnings of ($1.54) per share and revenue of $0.10 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 4:00 PM ET.

Lyra Therapeutics Stock Performance

LYRA stock remained flat at $0.47 during trading on Tuesday. The company had a trading volume of 22 shares, compared to its average volume of 53,314. Lyra Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $8.75. The business’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.92. The firm has a market capitalization of $843,125.00, a price-to-earnings ratio of -0.02 and a beta of 0.68.

Institutional Trading of Lyra Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in Lyra Therapeutics in the 3rd quarter valued at about $128,000. DRW Securities LLC bought a new position in shares of Lyra Therapeutics in the fourth quarter valued at approximately $52,000. Finally, Bank of America Corp DE grew its stake in Lyra Therapeutics by 33.7% during the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Lyra Therapeutics Company Profile

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).